Boston Scientific Welcomes Publication of Analysis Demonstrating Long-Term Survival Benefit for ICD Therapy

MADIT II Eight-Year Outcomes Analysis Shows That One Life is Saved for Every Eight Patients Who Receive an ICD

NATICK, Massachusetts, September 29, 2010 - Boston Scientific Corporation (NYSE: BSX) today welcomed the
publication of an analysis of long-term data from the MADIT II clinical trial
in the current issue of Circulation. The analysis demonstrates that the
life-saving benefits of implantable cardioverter defibrillator (ICD) therapy
are sustained at eight years. This is the first time that long-term data
regarding the benefits of ICDs in a primary prevention population have been
published in a peer-reviewed journal.

The analysis shows a sustainable mortality benefit over time,
including:

    - At eight years, one life is saved for every eight patients who receive
      an ICD. This represents a significant improvement over the
      two-year MADIT II data, which showed one life saved for every 17
      patients.
    - A 34 percent relative reduction in the risk of death for ICD
      patients at eight years (p<0.001, unadjusted).

"ICD therapy has proved effective in patients at risk of
sudden cardiac death, and now the long-term MADIT II data show the
life-saving benefits of these devices continue over time," said Arthur J.
Moss, M.D., Professor of Medicine at the University of Rochester Medical
Center and Principal Investigator of the MADIT, MADIT II and MADIT-CRT
trials.

The MADIT II study, sponsored exclusively by Boston
Scientific, was designed to determine whether ICDs improve survival when
compared to drug therapy alone in heart attack survivors with moderate
impairment of the left ventricle, the heart's main pumping chamber.

Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices whose products are used in a broad range of
interventional medical specialties. For more information, please visit:
www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934. Forward-looking statements may be
identified by words like "anticipate," "expect," "project," "believe,"
"plan," "estimate," "intend" and similar words. These forward-looking
statements are based on our beliefs, assumptions and estimates using
information available to us at the time and are not intended to be guarantees
of future events or performance. These forward-looking statements include,
among other things, statements regarding new product launches and launch
cadence, regulatory approvals, clinical trials, product performance and
competitive offerings. If our underlying assumptions turn out to be
incorrect, or if certain risks or uncertainties materialize, actual results
could vary materially from the expectations and projections expressed or
implied by our forward-looking statements. These factors, in some cases, have
affected and in the future (together with other factors) could affect our
ability to implement our business strategy and may cause actual results to
differ materially from those contemplated by the statements expressed in this
press release. As a result, readers are cautioned not to place undue reliance
on any of our forward-looking statements.

Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends; intellectual
property; litigation; financial market conditions; and, future business
decisions made by us and our competitors. All of these factors are difficult
or impossible to predict accurately and many of them are beyond our control.
For a further list and description of these and other important risks and
uncertainties that may affect our future operations, see Part I, Item 1A -
Risk Factors in our most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, which we may update in Part II, Item 1A -
Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file
hereafter. We disclaim any intention or obligation to publicly update or
revise any forward-looking statements to reflect any change in our
expectations or in events, conditions, or circumstances on which those
expectations may be based, or that may affect the likelihood that actual
results will differ from those contained in the forward-looking statements.
This cautionary statement is applicable to all forward-looking statements
contained in this document.

    CONTACT:
    Géraldine Varoqui
    Boston Scientific
    Public Relations International
    +49-170-7828-558
    varoquig@bsci.com

CONTACT: Géraldine Varoqui, Boston Scientific, Public Relations International, +49-170-7828-558, varoquig at bsci.com